Page 147 - Merck Sharp News Today

French failure to develop home-made Covid-19 vaccine prompts questions Issued on: Institut Pasteur facility, Lille. AFP - DENIS CHARLET 3 min The Pasteur Institute’s announcement that it is to stop further development of one of its potential Covid-19 vaccines, coming on the heels of Sanofis announcement that its vaccine will be delayed, has raised questions about medical research in France. Advertising Read more...

Regulatory News: NOXXON Pharma N.V. a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment , announced today the successful completion of its... | February 8, 2021

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals Lead Immunotherapy ISA101b with Keytruda® Combination aimed at priming and driving durable patient immune responses to cancer News provided by Share this article Share this article LEIDEN, The Netherlands, Jan. 26, 2021 /PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage company dedicated to developing rationally designed immunotherapeutics for oncology and infectious disease, today announced that the first patie...

(1) Combination aimed at priming and driving durable patient immune responses to cancer LEIDEN, The Netherlands, Jan. 26, 2021 /PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage company dedicated to developing rationally designed immunotherapeutics for oncology and infectious disease, today announced that the first patient has been dosed with its lead product ISA101b in a Phase II trial conducted and sponsored by UPMC Hillman Cancer Center, the University of Pittsburgh, PA, and supporte...

To print this article, all you need is to be registered or login on Mondaq.com. First published as part of Miriam Zanker, Suzy Roessel, Elizabeth Godfrey and Linda Xu, Current Developments - Australia: "Comprising": A double-edged sword - Merck Sharp & Dohme Corporation v Wyeth LLC (No 3) [2020] FCA 1477 (14 October 2020) and Not so sweet victory for wicked business: PDP Capital Pty Ltd v Grasshopper Ventures Pty LTd [2020] FCA 1078 (30 July 2020) (2020) 122 Intellectu...

January 22, 2021 Coronavirus Vaccine Mechanism Scientists around the world are working around the clock to manufacture a risk-free and effective COVID-19 vaccine. Currently, a handful of vaccines have been approved and are being provided to the public worldwide; a lot more vaccines are under development. Vaccine development involves various steps to ensure the final product is both safe and efficient. Initially, the fundamental research is carried out, once the vaccine candidate is manufactured...

Eagle Scout Alleges Gardasil HPV Vaccine Destroyed His Life From:   Eagle Scout Alleges Gardasil HPV Vaccine Destroyed His Life Michael "Mike" Colbath was a very active kid who loved the outdoors, ran cross-country and excelled in academics. Disabled since 14, Mike suffers ...

Share: New York, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Digital PCR Market Research Report by Product Type, by Technology, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06006671/?utm_source=GNW Market Statistics: The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency e...

Anaplasmosis Treatment Market 2020- Industry Latest Trends, Growth, Key Factors, Comprehensive Analysis, Outlook and Forecast

Share this article Share this article PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Companys lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends...